GB-AOS-1

GB-AOS-1 is a clinical-stage, lipid-based therapeutic developed by GlycosBio for the treatment of exocrine pancreatic insufficiency (EPI). It utilizes the company's proprietary Activated Oil System (AOS), which is designed to facilitate the digestion and absorption of fats in patients who lack sufficient pancreatic enzymes. Unlike traditional pancreatic enzyme replacement therapies (PERT) that rely on porcine-derived lipase, protease, and amylase, the AOS platform focuses on a structured lipid approach to manage malabsorption by providing 'activated' lipids that are more readily absorbed by the intestinal mucosa.